OAR 845-025-3265: Inhalable Cannabinoid Product Processor Requirements

(1) A processor may only use a non-cannabis additive in an inhalable cannabinoid product if the non-cannabis additive is accompanied by a list of ingredients from the manufacturer of the non-cannabis additive that: (a) In a header section, displays the name of the non-cannabis additive and the business name of the manufacturer of the non-cannabis additive; (b) In clear and legible font, includes a statement that the non-cannabis additive is for use in a product intended for human inhalation; (c) Accurately identifies all ingredients in the non-cannabis additive; and (d) For each ingredient of the non-cannabis additive, includes: (A) A Chemical Abstracts Service Reference Number that specifies the ingredient’s isomer and, if applicable, enantiomer; and (B) The ingredient’s concentration range within 20 percentage points. (2) A processor may not use a non-cannabis additive in an inhalable cannabinoid product that contains any amount of: (a) Squalene; (b) Squalane; (c) Vitamin E Acetate; (d) Triglycerides, including but not limited to Medium-Chain Triglyceride (MCT) Oil; or (e) Propylene Glycol, unless the product is going to be delivered through a metered dose inhaler whose functionality does not require combustion or heated vaporization. (3) On or after April 1, 2021, a processor may not manufacture or process an inhalable cannabinoid product that does not meet the requirements of this rule. (4) On or after July 1, 2021, a processor may not possess, sell, deliver, transfer, transport, purchase, or receive an inhalable cannabinoid product that does not meet the requirements of this rule. (5) Sanction. (a) An intentional violation of this rule is a Category II violation. (b) An unintentional violation of this rule is a Category III violation.